Sonoma Pharmaceuticals (SNOA)
Develops and manufactures shelf-stable hypochlorous-acid products for wound, skin, eye, foot, animal, and surface care.
Something off on this page? Send us feedback.
Sells shelf-stable hypochlorous-acid medical-device and consumer-health products for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. Revenue comes from product sales, partner distribution, custom-label development, contract manufacturing, licensing, and related technical assistance, with all production in Mexico.
Develops and manufactures shelf-stable hypochlorous-acid products under its Microcyn technology platform for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. Products span prescription, over-the-counter, office-dispense, consumer, and professional channels.
Monetizes formulations through direct professional and consumer sales, distributors, private-label and co-developed products, contract manufacturing, licensing, and some royalty or technical-assistance revenue. Human care supplies most revenue; sales extend across Europe, the United States, Asia, Latin America, and other markets.
Operates a partner-led model that combines product development, regulatory support, and manufacturing in Zapopan, Mexico. Products, manufacturing, labeling, distribution, and promotion depend on FDA and foreign-agency review, while all production is concentrated at the Mexico facility.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.3M · Total debt $739.0K · Total assets $18.1M · Shareholders' equity $6.6M
- Revenue
- $6.4M
- Operating income
- −$40.0K
- Net income
- −$330.0K
No dividends on record.
| Institutions | 6.58% | 110.8K shares | |
|---|---|---|---|
| 14 holders · as of Jun 30, 2026 | |||
| Other | 93.42% | 1.57M shares | |
| remainder | |||
1.68M company shares as of Sep 19, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (4.79M in the company's Sep 22, 2026 report, 1.68M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Renaissance Technologies LLCInstitution | 2.40% | 40,468 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.59% | 26,787 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 1.12% | 18,787 | as of Jun 30, 2026 |
Mckinley Carter Wealth Services, Inc.Institution | 0.66% | 11,193 | as of Jun 30, 2026 |
UBS Group AGInstitution | 0.46% | 7,808 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Solventum
Hospital wound-care alternative for cleansing and negative-pressure therapy.
- Smith & Nephew (ADR)
Global advanced-wound rival across dressings, infection management and NPWT.
- Organogenesis
Specialist advanced-wound rival in diabetic and chronic wound treatment.
- MiMedx
Placental-allograft rival for chronic, diabetic, and surgical wounds.
- Incyte
Prescription dermatology rival for atopic dermatitis treatment.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals | $1.27 | +1.60% | $2.1M | — | — | 0.1 | +59.6% |
| Solventum | $88.90 | +0.07% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Smith & Nephew (ADR) | $27.47 | −0.81% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Organogenesis | $1.49 | +6.16% | $180.1M | — | — | 0.4 | −56.7% |
| MiMedx | $4.88 | +1.43% | $701.1M | 120.2 | 49.1 | 2.0 | −34.7% |
| Incyte | $126.31 | +1.33% | $25.27B | 15.9 | 52.3 | 4.3 | +37.7% |
| Median | 17.4 | 49.1 | 1.9 | +2.2% |